Updated Securities Trading Policy
Released
Released
Announcement PDF
Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com
Updated Securities Trading Policy
19 November 2024 – Melbourne, Australia: Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) (“Neurizon” or
“the Company”), a clinical-stage biotech company advancing treatments for neurodegenerative diseases, advises
that pursuant to ASX Listing Rule 12.10, the Company attaches its updated Securities Trading Policy.
-ENDSThis announcement has been authorized for release by the Board of Neurizon Therapeutics Limited.
For further information, please contact:
Dr. Michael Thurn
Managing Director and Chief Execufive Officer
Neurizon Therapeufics Limited
enquiries@neurizon.com
+61 (3) 9692 7222
Catherine Strong
Sodali & Co
catherine.strong@sodali.com
+61 (0)406 759 268
About Neurizon Therapeutics Limited
Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing
treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the
treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate
access to effective ALS treatments for patients while exploring NUZ-001’s potential for broader neurodegenerative
applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating
new horizons for patients and families impacted by complex neural disorders.
Neurizon Investor Hub
We encourage you to ufilise our Investor Hub for any enquiries regarding
announcement or other aspects concerning Neurizon.
This plafform offers an opportunity to submit quesfions, share comments,
view video summaries of key announcements.
this
and
To access Neurizon Investor Hub please scan the QR code or visit
hftps://investorhub.neurizon.com
Level 4, 96-100 Albert Road, South Melbourne, VIC 3205 Tel: +61 3 9692 7222
SECURITIES TRADING POLICY
NEURIZON THERAPEUTICS LIMITED
ACN 094 006 023
Table of Contents
1.
Introduction ................................................................................................................. 4
2.
Objectives .................................................................................................................... 4
3.
Application .................................................................................................................. 4
4.
Meaning of Securities ................................................................................................ 5
5.
Insider Trading Rules ................................................................................................. 5
6.
Confidential Information ........................................................................................... 6
7.
Closed Periods ............................................................................................................ 6
8.
Restricted Trading ...................................................................................................... 7
9.
Excluded Trading ........................................................................................................ 7
10.
Exceptional Circumstances ................................................................................. 8
11.
Approval and Waiver ............................................................................................ 9
12.
Non-Compliance to the Policy or the Law ....................................................... 10
13.
Further Information.............................................................................................. 10
14.
Policy Review and Amendments ....................................................................... 11
15.
Annexure 1: Guidance Note: Who is Who .......................................................... 12
16.
Annexure 2: Trading Request Form (Illustrative Only) ................................... 14
Neurizon Therapeutics Limited (ACN: 094 006 023)
Securities Trading Policy | Version 1.0
Page 2 of 15
Document History
Version
Summary
of
Approved by
Approval date
Securities
Board of Directors
18 August 2021
Securities
Board of Directors
13 November 2024
Amendments
1.0
Initial
2.0
Review
Trading Policy
of
Trading Policy
Other Policy Details
Key Information
Details
Approval Body
Neurizon Therapeutics Limited Board of Directors
Key Stakeholders
Neurizon Therapeutics Limited Board of Directors
Neurizon Therapeutics Limited Senior Management
Company Secretary
Responsibility for
Implementation
Chief Executive Officer
Policy Custodian
Company Secretary
Next Review Date
November 2026
Legislative and Regulatory Framework
Authority
ASX Corporate
Governance Council
Australian
Government
Law, Resolution or Regulation
ASX
Corporate
Recommendation (2019)
Principles
and
(“ASX Principles”)
Corporations Act 2001 (Cth) (“Corporations Act”)
Neurizon Therapeutics Limited (ACN: 094 006 023)
Securities Trading Policy | Version 1.0
Governance
Page 3 of 15
1.
Introduction
1.1.
This Securities Trading Policy (the “Policy”) sets out the policy of Neurizon
Therapeutics Limited (the “Company”, “NUZ”, “we”, “us” or “our”) on dealings by
directors of the Company (the “Directors”) and employees in:
(a)
securities of the Company (“Company Securities”); and
(b)
securities of other entities.
2.
Objectives
2.1.
The Corporations Act prohibits any person/ company (“Insider”) in possession of
non-public, price-sensitive information (“Inside Information”) from acquiring or
disposing of securities or passing on the Inside Information to other people who
may deal in securities.
2.2.
This Policy is intended to:
(a)
ensure that all Directors, employees and contractors of the Company (and
their associates) are aware of the trading restrictions when trading in
Company Securities; and
(b)
protect the reputation of the Company and its Directors by seeking to avoid
the possibility that misconceptions, misunderstandings or suspicions might
arise as a result of trading by Directors and others who may be, or be
perceived to be, in possession of Inside Information.
2.3.
This Policy seeks to do so by imposing additional restrictions on the trading of
2.4.
It is each Relevant Person’s responsibility to ensure that they are fully aware of their
3.
Application
3.1.
This Policy applies to:
securities by Relevant Persons (as defined below).
legal obligations with respect of securities dealings.
(a)
all Directors and officers of the Company (including the CEO);
(b)
all direct reports to the CEO;
(c)
all other employees of the Company (including consultants and
contractors); and
(collectively “Relevant Persons”)
(d)
3.2.
“Closely Related Persons” (as the term is defined in the Corporations Act) of
all persons prescribed under 3.1 (a) to (c).
Relevant Persons must take appropriate steps to ensure that their closely related
persons do not breach this, Policy. Accordingly, where this Policy requires a Relevant
Neurizon Therapeutics Limited (ACN: 094 006 023)
Securities Trading Policy | Version 1.0
Page 4 of 15
Person to obtain clearance, that person must also do it for their Closely Related
Persons or ensure that their Closely Related Persons do it.
3.3.
Annexure 1 contains a Guidance Note assisting with the definitions used in this
4.
Meaning of Securities
4.1.
For the purposes of this Policy, "Company Securities" means shares, debentures,
Policy, in particular ‘Closely Related Persons’.
options to subscribe for new shares and options over existing shares, warrant
contracts, and other derivatives relating to the shares.
5.
Insider Trading Rules
5.1.
Prohibition
5.1.1.
If you have any Inside Information (see definition in Section 5.3) about the
Company (or another relevant entity, such as a company with which the NUZ is
considering a transaction) which is not publicly known, it is a criminal offence for
you to:
(a)
trade in Company Securities (or securities of the other relevant entity);
(b)
advise or procure another person to trade in Company Securities (or
(c)
pass on Inside Information to someone else (including colleagues, family or
securities of the other relevant entity); or
friends) knowing (or where you should have reasonably known) that the
other person will, or is likely to, use that information to trade in, or procure
someone else to trade in, Company Securities (or securities of the other
relevant entity).
5.2.
Consequences of insider trading
5.2.1.
This offence, called "insider trading", can subject you to:
(a)
criminal liability including large fines and/or imprisonment (or both)
(b)
a civil penalty (fine) of up to hundreds of thousands of dollars; and
(c)
civil liability, which may include being sued for any loss suffered as a result
of illegal trading.
5.3.
Inside Information
5.3.1.
"Inside information" is information that:
(a)
price sensitive;
(b)
is not generally available; and
(c)
if it were generally available, a reasonable person would expect that it would
(or would be likely to) influence investors in deciding whether to buy or sell
particular securities.
Neurizon Therapeutics Limited (ACN: 094 006 023)
Securities Trading Policy | Version 1.0
Page 5 of 15
5.3.2.
The financial impact of the information is important, but strategic and other
implications can be equally important in determining whether information is Inside
Information. The definition of information is broad enough to include rumours,
matters of supposition, intentions of a person (including the Company) and
information which is insufficiently definite to warrant disclosure to the public.
5.3.3.
Importantly, you need not be an "Insider" to come across Inside Information. That is,
it does not matter how you come to know the Inside Information (for example, you
could learn it in the course of carrying out your responsibilities or in passing in the
corridor or in a lift or at a dinner party).
5.3.4.
Examples of Insider Information, include the following (but are not limited to);
(a)
a material variance in the financial performance of the Company;
(b)
a possible acquisition or sale of any assets by the Company;
(c)
a possible change in the Company's capital structure;
(d)
a proposed dividend;
(e)
senior management changes;
(f)
positive or negative outcomes of key clinical trials;
(g)
intellectual property developments; or
(h)
any possible claim against the Company or other unexpected liability.
5.3.5.
Insider trading is prohibited at all times.
5.3.6.
If you possess Inside Information, you must not buy or sell Company Securities,
advise or get others to do so or pass on the Inside Information to others. This
prohibition applies regardless of how you learn the information.
5.3.7.
The prohibition on insider trading applies not only to information concerning
Company Securities. If a person has Inside Information in relation to securities of
another company, that person must not deal in those securities.
6.
Confidential Information
6.1.
Relevant Persons also have a duty of confidentiality to the Company.
6.2.
You must not reveal any Confidential Information concerning the Company, use
that information in any way that may injure or cause loss to the Company, or use
that confidential information to gain an advantage for yourself.
7.
Closed Periods
7.1.
Relevant Persons must not deal in Company Securities:
(a)
without prior approval (refer to Section 11- Approval and Waiver);
(b)
during any Closed Periods.
Neurizon Therapeutics Limited (ACN: 094 006 023)
Securities Trading Policy | Version 1.0
Page 6 of 15
7.2.
Closed periods, refer to times when Relevant Persons with access to Inside
7.3.
Closed Periods are crucial for ensuring compliance with insider trading laws and
7.4.
NUZ’s Closed Periods are;
Information, are restricted from trading Company Securities.
maintaining investor confidence.
(a)
the period each year from the close of trading at the end of the full financial
year until 10.00am on the next trading day following the announcement to
ASX of the year-end results (‘Appendix 4E’);
(b)
the period each year from the close of trading at the end of the financial
half-year until 10.00am on the next trading day following the announcement
of the half-yearly results (‘Appendix 4D’).
7.5.
Notwithstanding clause 8.3, the Board may impose other Closed Periods from time
7.6.
The Company Secretary will notify all Relevant Persons of the opening and closing
to time (i.e. results of clinical trials, regulatory approvals, etc.).
dates of Closed Periods windows, and any period determined by the Board to be a
Closed Period.
8.
Restricted Trading
8.1.
Relevant Persons should not trade in Company Securities on a short-term basis or
for speculative trading gain. The Company considers “short-term” to be a period
of 6 months or less.
8.2.
Relevant Persons must not enter into margin lending or other secured financing
8.3.
Relevant Persons must not enter into transactions with securities (or any derivative
arrangements in respect of the Company’s securities.
thereof) which limit the economic risk of any unvested entitlements awarded under
an equity-based remuneration scheme, or otherwise awarded, or which will be
offered by the Company in the future (e.g., hedging).
9.
Excluded Trading
9.1.
Trading that is not covered by the restrictions in this Policy, includes:
(a)
transfer of securities in a superannuation fund or other saving scheme in
which the Relevant Person is a beneficiary, but the Relevant Person has no
control or influence over the investment decisions made by the
superannuation fund or saving scheme.
(b)
a disposal of Company Securities arising from the acceptance of a takeover
offer, scheme of arrangement, or equal access buy-back;
Neurizon Therapeutics Limited (ACN: 094 006 023)
Securities Trading Policy | Version 1.0
Page 7 of 15
(c)
an investment in, or trading units of, a fund or other scheme (other than a
scheme only investing in Company Securities) where the assets of the fund
or other scheme are invested at the discretion of a third party;
(d)
a disposal of rights acquired under a pro rata issue;
(e)
an acquisition of Company Securities under a security purchase plan, pro
rata issue or dividend purchase plan where the Relevant Person did not
commence or amend their participation in the plan during a Closed Period;
(f)
an acquisition of Company Securities under an employee incentive scheme
(however, the additional restrictions in his policy apply to any subsequent
trade of any Company Securities issued to (or for the benefit of) a Relevant
Person under an employee incentive scheme;
(g)
the exercise (but not the sale of Company Securities following exercise) of
an option or right under an employee incentive scheme, or the conversion
of a convertible security, where the final date for exercise or conversion falls
during a Closed Period and the Relevant Person could not reasonably have
been expected to exercise it at a time outside the Closed Period;
9.2.
Relevant Persons are reminded that they must still comply with the insider trading
laws even where they would otherwise be permitted to trade in Company Securities
or after separating from the Company (i.e. resignation).
10.
Exceptional Circumstances
10.1.
If a Relevant Person needs to deal in Company Securities due to exceptional
circumstances but such dealing would breach this Policy, the Relevant Person must
apply to the person specified in Section 12 for a waiver.
10.2.
Whether severe financial hardship or other exceptional circumstances exist is to be
determined by the Managing Director/ CEO or, in the case of the Managing
Director/CEO, by the Board in its sole and absolute discretion.
10.3.
Exceptional circumstances may include:
(a)
severe financial hardship which means a Relevant Person has a pressing
financial commitment that cannot be satisfied otherwise than by selling the
securities. For example, the tax liability of a Relevant Person would not
normally constitute severe financial hardship unless the Relevant Person
has no other means of satisfying the liability;
(b)
if the Relevant Person is required by a court order, or there are courtenforceable undertakings to transfer or sell the securities or there is some
other overriding legal or regulatory requirement for the Relevant Person to
do so; or
Neurizon Therapeutics Limited (ACN: 094 006 023)
Securities Trading Policy | Version 1.0
Page 8 of 15
(c)
a situation determined by the Chair or, in the case of the Chair, the
remaining Directors, to be an exceptional circumstance.
11.
Approval and Waiver
11.1.
Relevant Persons are only permitted to deal in Company Securities if they have
given notice and obtained approval as set out below (and on the basis that the
prohibition prescribed in Section 5- Insider Rules does not apply), through the
Trading Request Form.
Relevant Person
Approval
Chair of the Board *
Board
Directors*
Chair of the Board
Officers of the
Company (including
the CEO)
Employees and any
other Relevant
Persons
Chair of the Board
Managing
Director/CEO
Notification
Notification
Period
The Board and the
1 day prior to
The Board and the
1 day prior to
The Board and the
1 day prior to
Company Secretary
Company Secretary
Company Secretary
Managing Director
and Company
trade
trade
trade
1 day prior to
Secretary
trade
* Note: The Directors of the Company are required to provide to the Company Secretary all of the
information necessary for the completion of Appendix 3Y (Change of Director's Interest) forms as soon
as practicable after the dealing they have undertaken has taken place so that they can be filed with
the ASX for the purposes of Section 205G of the Corporations Act and Listing Rule 3.19A.
11.2.
Upon:
(a)
provision of notification; and
(b)
confirmation by the Company Secretary that there is no objection to the
person trading,
the Relevant Person may undertake the proposed dealing
11.3.
A decision to grant a waiver may be given or refused, without giving reasons. Once
11.4.
If a waiver is granted, the Relevant Person will be notified in writing (which may
given, a waiver can also be withdrawn if new circumstances come to light.
include notification via email) and in each circumstance, the duration of the waiver
to deal in securities will be 5 business days.
11.5.
If a waiver is refused, the Relevant Person must keep that confidential.
11.6.
Once a Relevant Person has completed a trade in Company Securities, the
Company Secretary must be:
Neurizon Therapeutics Limited (ACN: 094 006 023)
Securities Trading Policy | Version 1.0
Page 9 of 15
(a)
advised that the trade has been completed within 2 business days; and
(b)
in the case of Directors, provided with sufficient information to enable the
Company to comply with the requirements to notify a change of interests to
ASX (file 3Y forms) within 5 business days of any dealing by a Director.
11.7.
The notification obligations operate at all times.
12.
Non-Compliance to the Policy or the Law
12.1.
Breaches of the insider trading laws have serious consequences for both the
12.2.
A person who contravenes or is involved in a contravention of the provisions of this
Relevant Person concerned and the Company.
Policy or the Law may also be liable to compensate any person who suffers loss or
damage resulting from the conduct. In addition, an actual or suspected breach of
the insider trading Laws may also give rise to adverse public scrutiny and media
comment and reputation damage.
12.3.
It is important that Relevant Persons adhere to this Policy at all times.
12.4.
Any person who breaches this Policy may face suspension or termination of
12.5.
Further consequences may include:
12.6.
employment or contract or other disciplinary action.
(a)
forfeiture of Company securities;
(b)
reporting of breaches to the Company’s auditors and/or to ASIC or another
(c)
loss of other entitlements, including loss of rights relating to Company
(d)
forfeiture of bonuses, including but not limited to performance bonuses or
relevant regulator/s;
incentive or share schemes; and
project related bonuses.
Note that proof of breach by the Company or successful prosecution by a regulator
is not required to discipline, suspend, or terminate an employee or contractor. It
may be sufficient that, in the opinion of the Company, there has been behaviour
constituting serious or wilful misconduct. The Company may form a view that there
has been a breach of obligations of confidentiality, a breach of good faith and
fidelity, and/or a conflict of interest.
13.
Further Information
13.1.
Employees should contact the Company Secretary if they are unsure about
whether it is acceptable to deal or communicate with others in relation to the
Company's Securities or other securities or if they have any other queries about this
Policy.
Neurizon Therapeutics Limited (ACN: 094 006 023)
Securities Trading Policy | Version 1.0
Page 10 of 15
14.
Policy Review and Amendments
14.1.
This Policy will be reviewed and approved by the Board on at least once every two
years to ensure that it remains effective and meets the ASX Listing Rules and the
Corporations Act.
14.2.
This Policy cannot be amended without written approval from the Board.
Neurizon Therapeutics Limited (ACN: 094 006 023)
Securities Trading Policy | Version 1.0
Page 11 of 15
15.
Annexure 1: Guidance Note: Who is Who
15.1.
Relevant Personnel are as follows:
all directors and officers of the Company (including key management
personnel);
the senior management team;
employees;
from time-to-time Consultants who are engaged by the Company; and;
closely related persons of the parties listed above.
15.2.
Relevant Persons are those parties described in this Policy together with any
15.3.
All Company Personnel can trade in Company securities upon being granted
15.4.
Closely related persons are defined in the Corporations Act in a complex manner,
closely related persons of those Relevant Persons.
approval following the submission of a Trading Request Form (Annexure 2):
and it is important to understand or get advice if you are unsure. Broadly, it is as
follows:
15.5.
(a)
a spouse or child; or
(b)
a child of the person’s spouse; or
(c)
a dependant of the person or of the person’s spouse; or
(d)
a company the person controls; or
(e)
a person prescribed by the Corporations Regulations.
You may need assistance in determining who is a closely related person. It may not
always be clear and obvious, so please seek advice from the Company Secretary.
For example, your closely related parties will include:
a) your children;
b) your stepchildren;
c) your partner’s children;
d) your wife / husband;
e) your partner’s grown children from a previous marriage;
f) close members of your family / who influence you, and may also include:
g) your superannuation fund; and
h) any other company you are on the board of.
15.6.
Closely related persons are also prohibited from voting on resolutions at the
Company’s general meetings that relate to directors’ remuneration. This can mean
Neurizon Therapeutics Limited (ACN: 094 006 023)
Securities Trading Policy | Version 1.0
Page 12 of 15
that the above people and entities cannot vote at the Company’s shareholder
meetings on such matters.
15.7.
You should seek advice from the Company Secretary on this if required, particularly
if you are a director or officer, or a closely related person of a director or officer of
the Company.
Neurizon Therapeutics Limited (ACN: 094 006 023)
Securities Trading Policy | Version 1.0
Page 13 of 15
16.
Annexure 2: Trading Request Form (Illustrative Only)
From:
(print Relevant Person’s name)
Position:
(print job title/ position)
Purchasing Entity:
(if applicable)
To:
[INSERT]
[INSERT TITLE]
Neurizon Therapeutics Limited
TRADING OF COMPANY SECURITIES
In accordance with the Neurizon Therapeutics Limited Securities Trading Policy, I give
notice to you that I am proposing to deal with securities in the Company (‘Company
Securities’) in the following manner (tick one):
buy Company Securities
sell Company Securities
transfer Company Securities vested under an equity incentive plan to me
transfer Company Securities to a related party (e.g. family company, trust or
superannuation fund)
exercise options over Company Securities
utilise derivatives and enter a hedging transaction
The number of securities that I propose to deal with is up to
(number).
The transaction will be carried out on-market/ off-market (delete one).
The transaction is proposed to be carried out in the
days between
(date) and
(number no more than 5) business
(date).
I confirm that I have no inside information and will comply with the Company's securities
trading policy in relation to my dealings.
I agree to notify the Company Secretary of the results of this action within 2 business days
of the action.
Please confirm that I am cleared to deal in Company securities in the manner set out
above.
Signed:
(by the Relevant Person requesting clearance)
Date signed:
Neurizon Therapeutics Limited (ACN: 094 006 023)
Securities Trading Policy | Version 1.0
Page 14 of 15
I confirm that subject to you not gaining any Inside Information, you are authorised to deal
in Company Securities for the 5 business days following the approval date.
[Insert]
[Insert]
Date approved:
Date approved:
Neurizon Therapeutics Limited (ACN: 094 006 023)
Securities Trading Policy | Version 1.0
Page 15 of 15
Share your feedback
Discover